Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Glutaraldehyde

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    12 result(s) found for: Glutaraldehyde. Displaying page 1 of 1.
    EudraCT Number: 2019-002811-25 Sponsor Protocol Number: DMV03-SIT-027 Start Date*: 2020-11-13
    Sponsor Name:Inmunotek, S.L.
    Full Title: Prospective, multicenter, randomized, double-blind, placebo-controlled clinical trial of efficacy and safety with subcutaneous immunotherapy in patients with mild to moderate rhinitis / rhinoconjun...
    Medical condition: Allergic rhinitis / rhinoconjunctivitis with or without mild to moderate asthma due to sensitization to grass and olive pollen
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004870 10036019 Pollen allergy LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-002865-37 Sponsor Protocol Number: DMV02-SIT-026 Start Date*: 2020-11-13
    Sponsor Name:Inmunotek, S.L.
    Full Title: A Randomized, Double-Blinded, Placebo-Controlled, Prospective, Multicenter Clinical Trial to Evaluate the Efficacy and Safety of Subcutaneous Immunotherapy in Patients With Rhinitis With or Without...
    Medical condition: Allergic rhinitis / rhinoconjunctivitis with or without mild to moderate asthma due to sensitization to grass and cupressaceae pollen
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004870 10036019 Pollen allergy LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-000513-29 Sponsor Protocol Number: CLU-2008-001 Start Date*: 2008-09-30
    Sponsor Name:ROXALL Medizin GmbH
    Full Title: Efficacy and safety of subcutaneous cluster immunotherapy with cluster-allergoid CLUSTOID® (glutaraldehyde-polymerized allergen extract of mixtures of grass and rye allergens – Holcus lanatus, Dact...
    Medical condition: This clinical trial will evaluate the benefit of subcutaneous cluster immunotherapy with cluster-allergoid CLUSTOID® over placebo in patients with allergic rhinoconjunctivits.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-003715-22 Sponsor Protocol Number: DMV01-SIT-015 Start Date*: 2020-11-04
    Sponsor Name:Inmunotek, S.L.
    Full Title: Prospective, randomized, placebo-controlled, multi-center trial comparing the efficacy and safety of subcutaneous immunotherapy with a mixture of grasses and mites at adequate doses versus monother...
    Medical condition: Mild to moderate asthma and allergic rhinitis / rhinoconjunctivitis (intermittent or persistent) due to hypersensitivity to house dust mites (Dermatophagoides pteronyssinus and / or D. farinae) and...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004853 10001728 Allergic rhinoconjunctivitis LLT
    21.1 100000004855 10034382 Perennial allergic rhinitis LLT
    20.0 100000004870 10020419 House dust mite allergy LLT
    20.0 100000004870 10036019 Pollen allergy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-003065-14 Sponsor Protocol Number: 6078-PG-PSC-141 Start Date*: 2007-02-26
    Sponsor Name:LETI Pharma GmbH
    Full Title: Investigation of a preseasonal rush treatment scheme with Depigoid® Grass Mix as an add-on therapy in patients with allergic rhinitis and/or rhinoconjunctivitis sensitized to grass pollen
    Medical condition: Intermittent rhinitis and/or rhinoconjunctivitis with or without asthma bronchial caused by clinical relevant sensitisation against grass pollen.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10039083 Rhinitis LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-008448-26 Sponsor Protocol Number: 603-PG-PSC-173 Start Date*: 2009-10-20
    Sponsor Name:LETI Pharma GmbH
    Full Title: Randomized, double-blind, parallel group, multicenter study to evaluate the efficacy and safety of four doses of depigmented glutaraldehyde polymerized birch pollen allergenic extract (Depigoid® Bi...
    Medical condition: Allergic rhinitis and/or rhinoconjunctivitis, with or without intermittent asthma, caused by birch pollen.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001723 Allergic rhinitis LLT
    9.1 10039097 Rhinoconjunctivitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) LT (Completed)
    Trial results: View results
    EudraCT Number: 2006-005269-20 Sponsor Protocol Number: 6078-PG-PSC-158 Start Date*: 2007-01-15
    Sponsor Name:LETI Pharma GmbH
    Full Title: Randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy of Depigoid® Grass Mix as a rush immunotherapy in patients with allergic rhinitis using an environmental ...
    Medical condition: Allergic rhinitis and/or rhinoconjunctivitis with or without mild intermittent asthma caused by clinical relevant sensitization against grass pollen.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10039083 Rhinitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-000172-26 Sponsor Protocol Number: 1301-PG-PSC-203 Start Date*: 2014-06-26
    Sponsor Name:Laboratorios LETI S.L.U
    Full Title: A multicentre, open label, phase IIb clinical trial to evaluate safety, tolerability and efficacy of the depigmented modified allergen extract of two mites mixes at 200 DPP/ml (DP/MG/14-1 Dermatoph...
    Medical condition: Allergic rhinitis or rihinoconjuntivitis, with controlled allergic asthma due to D. pteronyssinus and Blomia tropicalis or Lepidoglyphus destructor sensitization.
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004870 10020419 House dust mite allergy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2006-005868-10 Sponsor Protocol Number: 6043-PG-PSC-153 Start Date*: 2007-07-24
    Sponsor Name:Laboratorios LETI S.L.
    Full Title: Ensayo clínico, multicéntrico, aleatorizado, doble ciego controlado con placebo, de inmunoterapia subcutánea con extracto despigmentado y polimerizado de polen de Phleum pratense en pacientes con h...
    Medical condition: Rinoconjuntivitis moderada-severa (con o sin asma episódico) inducida por hipersensibilidad frente al polen de gramíneas.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10039097 Rhinoconjunctivitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed) HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-005597-43 Sponsor Protocol Number: RG_06-280 Start Date*: 2008-02-04
    Sponsor Name:University of Birmingham [...]
    1. University of Birmingham
    2. Birmingham Heartlands Hospital
    Full Title: Topical Retinoids and Diabetic Neuropathic Ulceration
    Medical condition: The overall goal of the proposal is to assess the capacity of topical retinoid treatment to induce changes in connective tissue metabolism (i.e., increased collagen production and decreased elabora...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10050712 Vitamin A LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-000414-11 Sponsor Protocol Number: 603-PG-PSC-191 Start Date*: 2012-08-31
    Sponsor Name:LETI Pharma GmbH
    Full Title: Multicenter, placebo-controlled, long-term study of Depigoid Birch 5000 in adults and adolescents with allergic rhinitis and/or rhinoconjunctivitis with or without intermittent asthma
    Medical condition: Seasonal allergic rhinitis and/or rhinoconjunctivitis with or without intermittent asthma due to birch pollen allergy
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004870 10066093 Birch pollen allergy LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) LT (Completed) CZ (Completed) FI (Completed) PL (Completed) LV (Completed)
    Trial results: View results
    EudraCT Number: 2011-004185-14 Sponsor Protocol Number: CDPG103ADE01 Start Date*: 2012-02-29
    Sponsor Name:Novartis Pharma GmbH
    Full Title: A multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of intraseasonal specific short-term immunotherapy with depigmented glutaraldeh...
    Medical condition: Allergic rhinitis and/or rhinoconjunctivitis with or without intermittent asthma.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10015919 - Eye disorders 10001728 Allergic rhinoconjunctivitis LLT
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10039776 Seasonal allergic rhinitis LLT
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10001705 Allergic asthma LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 13 16:26:57 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA